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Translocation t(2p;3q) is a rare but recurrent finding in myeloid disorders. We present the
first case of primary myelofibrosis with t(2;3)(p21;q26) as the sole chromosomal anomaly. The compari-
son with the 11 other previously published myeloid-associated t(2p;3q) cases confirms that this nonran-
dom translocation involves a pluripotent stem cell and is associated with a poor prognosis. © Elsevier




Chromosomal translocations involving the short arm of
chromosome 2 and the distal part of chromosome 3 long
arm have been described in hematological malignancies.
Several authors highlighted the nonrandom nature of
these translocations in myeloid malignancies. Only 11
previous cases of t(2;3)(p13–23;q26–29) associated with
myeloid disorders have been published [1–9] (Table 1).
Except for three cases of acute myeloid leukemia M2
(AML M2), this nonrandom chromosomal rearrangement
is observed with other anomalies and considered a sec-
ondary karyotypic aberration [1].
In the present report, we describe, to our knowledge,
the first case of primary myelofibrosis with t(2;3)((p21;q26)




A 68-year-old man was admitted to the hospital because of
epistaxis, pallor, weight loss, and severe left upper quad-
rant pain. He reported chills, sweats, and dyspnea. Ab-
dominal examination revealed moderate hepatomegaly
and major splenomegaly. No lymphadenopathy was found.
















6% myelocytes, 1% promyelocytes, and 7% blasts. Bone
marrow aspiration was difficult and disclosed no stroma.
Mild basophil leucocytosis and thrombocytopenia were
noted. An excess of myeloblasts (7.2%), elliptocytes, dac-
rocytes, schizocytes, and basophils was also observed. 71.5%
(peripheral blood) and 82.8% (bone marrow) of the blasts









chronic myeloproliferative disorder was suspected. Cyto-
genetic studies performed at diagnosis on 24-hour BM cul-





type (Fig. 1). Fluorescence in situ hybridization using the
BCR and ABL probes (Oncor Inc., Gaithersburg, MD) con-
firmed the absence of the chronic myeloid leukemia (CML)-
associated molecular rearrangement.
Splenectomy was performed 2 weeks after diagnosis.
The spleen was greatly enlarged (weight: 3,900 g) and deep
purple-red with indistinct white pulp. The subcapsular
area showed hematomas. Microscopic examination re-
vealed variable degrees of fibrosis of all the hematopoietic
cell lines in the red pulp sinuses and in the cords of Bill-
roth. New samples of bone marrow and blood were received
at the same time. Peripheral blood showed leucoerythro-
blastic blood film with striking poikilocytosis, including
teardrop poikilocytes. Bone marrow again disclosed no





















L) with 34% of blasts and
1.6% of micromegakaryocytes were observed. The diagnos-
tic of myelofibrosis in transformation was made. The patient




To the best of our knowledge, this is the first report of a
t(2;3)(p21;q26) translocation in a case of myelofibrosis.
Similar translocations have been published previously in
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11 patients with other myeloid disorders (6 AML cases, 3
MDS, and 2 CML blast phase patients) (Table 1). In the
great majority of these reports, t(2;3) appears to be a sec-
ondary event, indicative of a poor prognosis. Only three
cases of AML M2 showed the translocation as an isolated
anomaly. In the other reports, the chromosomal rearrange-
ment was found associated with other chromosomal aber-




or deletions of chromosomes 5
and 7 (Table 1), confirming the already mentioned strong
association between these rearrangements and 3q26 ab-
normalities [10–12]. In our case, however, t(2;3) was the
sole anomaly but its presence coincided with rapid blastic
transformation of myelofibrosis. The same conclusion can
be drawn from CML patients where the detection of the
t(2p;3q) coincided with rapid conversion to blast crisis
[8, 9]. Our observation also confirms previously established
correlations between rapid blastic transformation and 3q
abnormalities [13, 14]. Other common features of 3q26 ab-
errations are also encountered, such as an abnormal plate-
let count and micromegakaryocytes [14]. Finally, our
observation further confirms that t(2;3) appears in a pluri-
potent stem cell, is associated with a poor prognosis, and
constitutes a nonrandom chromosomal anomaly associ-
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Patient, diagnostic, and cytogenetic data from the 11 previously published t(2;3) cases 
associated with myeloid disorders
 
Patient data Disease Karyotype Ref.




7,del(12)(p12) Berger et al. [1]
F/10 AML M2 46,XX,t(2;3)(p22;q28) Berger et al. [1]
M/74 AML M2 46,XY,t(2;3)(p13;q28) Prigogina et al. [2]
M/16 AML M2 46,XY,t(2;3)(p13;q26) Fleischman et al. [9]




7 Levaltier et al. [3]



















7 Bitter et al. [7]
F/30 CML (blastic phase) 46,XX,t(9;22)(q34;q11)[3]46,XX,t(2;3)(p13;q26),
t(9;22)(q34;q11)[8]
Kwong et al. [8]
M/16 CML (blastic phase) 46,Y,der(X)t(X;9)(p22;q22),t(2;3)(p13;q26),
t(9;22)(q34;q11)
Fleischman et al. [9]
Figure 1 Karyotype of the bone marrow cells at diagnosis. Arrows indicate the abnormal chromosomes.
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